Volume 31, Issue 204 (1-2022)                   J Mazandaran Univ Med Sci 2022, 31(204): 172-177 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ranjbarnejad F, Aznab M, Mansouri K, Farrokhi A, Ranjbarnejad T, Rezazadeh D. Coexistence of BCR-ABL1 Translocation and JAK2 V617F Mutation in a Patient with Chronic Myeloid Leukemia Under Long-term Treatment with Imatinib and Nilotinib: A Case Report. J Mazandaran Univ Med Sci 2022; 31 (204) :172-177
URL: http://jmums.mazums.ac.ir/article-1-16807-en.html
Coexistence of BCR-ABL1 Translocation and JAK2 V617F Mutation in a Patient with Chronic Myeloid Leukemia Under Long-term Treatment with Imatinib and Nilotinib: A Case Report
Fatemeh Ranjbarnejad , Mozafar Aznab , Kamran Mansouri , Alireza Farrokhi , Tayebeh Ranjbarnejad , Davood Rezazadeh
Abstract:   (958 Views)
 This report describes an 89-year-old woman diagnosed with Philadelphia positive Chronic Myeloid Leukemia in 2007 who was initially treated with 200 mg/day imatinib. The patient demonstrated complete molecular response (CMR) in two tests in 2015 and 2018. During treatment between 2007 and 2019, despite increased dosage of imatinib and switching her therapy to nilotinib, complete hematological response was not obtained. ARMS-PCR was performed to find the possible cause of this failed response and JAK2 V617F mutation was detected. The patient with no BCR/ABL1 transcript showed a relatively good molecular response to nilotinib, although the complete hematological response was not observed. According to our findings, tyrosine kinase inhibitor could not be an effective therapy in this JAK2 V617F-positive MPN patient with a BCR/ABL1 mutation.
Keywords: imatinib, chronic myeloid leukemia, nilotinib, BCR-ABL1, JAK2 V617F
Full-Text [PDF 570 kb]   (418 Downloads)    
Type of Study: Case Report | Subject: Hematology and Oncology
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Mazandaran University of Medical Sciences

Designed & Developed by : Yektaweb